HK1214526A1 - 眼底疾病治療劑 - Google Patents
眼底疾病治療劑Info
- Publication number
- HK1214526A1 HK1214526A1 HK16102561.7A HK16102561A HK1214526A1 HK 1214526 A1 HK1214526 A1 HK 1214526A1 HK 16102561 A HK16102561 A HK 16102561A HK 1214526 A1 HK1214526 A1 HK 1214526A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- therapeutic agent
- eyeground
- disease
- eyeground disease
- therapeutic
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013090851 | 2013-04-24 | ||
| PCT/JP2014/001123 WO2014174747A1 (ja) | 2013-04-24 | 2014-03-03 | 眼底疾患治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1214526A1 true HK1214526A1 (zh) | 2016-07-29 |
Family
ID=51416925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102561.7A HK1214526A1 (zh) | 2013-04-24 | 2016-03-07 | 眼底疾病治療劑 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20160339018A1 (zh) |
| EP (2) | EP2990040B1 (zh) |
| JP (1) | JP5557408B1 (zh) |
| KR (1) | KR102177199B1 (zh) |
| CN (1) | CN105050600B (zh) |
| HK (1) | HK1214526A1 (zh) |
| TW (1) | TWI629985B (zh) |
| WO (1) | WO2014174747A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015229671A (ja) * | 2014-06-06 | 2015-12-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 網膜色素上皮細胞保護剤 |
| EP3199155B1 (en) | 2014-09-24 | 2021-06-16 | Kowa Company, Ltd. | Corneal thickness modulating agent |
| DK3199161T3 (da) * | 2014-09-25 | 2022-01-03 | Kowa Co | Farmaceutisk præparat |
| MY177032A (en) | 2014-09-25 | 2020-09-02 | Kowa Co | Aqueous composition |
| JP2016135780A (ja) * | 2015-01-16 | 2016-07-28 | 興和株式会社 | 水性組成物 |
| KR20160108121A (ko) | 2015-03-06 | 2016-09-19 | 코와 가부시키가이샤 | 수성 조성물 |
| WO2017064119A1 (en) * | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| EP4088719A1 (en) * | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| JP6928479B2 (ja) | 2017-05-12 | 2021-09-01 | 学校法人順天堂 | 拒絶反応抑制剤 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0349482A (ja) | 1989-07-18 | 1991-03-04 | Matsushita Electric Ind Co Ltd | ファインダー表示装置 |
| CN1155383C (zh) * | 1995-12-21 | 2004-06-30 | 阿尔康实验室公司 | 某些异喹啉磺酰基化合物治疗青光眼及眼局部缺血的用途 |
| EP0956865B2 (en) | 1996-08-12 | 2010-08-18 | Mitsubishi Tanabe Pharma Corporation | MEDICINES COMPRISING Rho KINASE INHIBITOR |
| JP4316794B2 (ja) | 1997-10-22 | 2009-08-19 | 株式会社デ・ウエスタン・セラピテクス研究所 | イソキノリン誘導体及び医薬 |
| JP4212149B2 (ja) * | 1998-06-11 | 2009-01-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 医薬 |
| EP1459743B9 (en) | 1998-08-17 | 2012-08-01 | Senju Pharmaceutical Co., Ltd. | Agent for prophylaxis and treatment of glaucoma |
| CA2443918C (en) | 2001-04-11 | 2012-06-05 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents containing rho kinase inhibitors |
| US20040266755A1 (en) * | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
| GB0425026D0 (en) | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
| JP2008519814A (ja) * | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
| MY139797A (en) * | 2004-11-29 | 2009-10-30 | Kowa Co | (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate |
| US20060142270A1 (en) * | 2004-12-23 | 2006-06-29 | Kowa Co., Ltd. | Preventing or treating agent for glaucoma |
| TWI367098B (en) * | 2004-12-23 | 2012-07-01 | Kowa Co | Treating agent for glaucoma |
| DE602006021704D1 (de) * | 2005-02-25 | 2011-06-16 | Kowa Co | Verfahren zur herstellung eines 4-fluorisochinolin-5-sulfonylhalogenids oder eines salzes davon |
| JP2006290827A (ja) * | 2005-04-13 | 2006-10-26 | Kowa Co | 緑内障予防又は治療剤 |
| WO2006115244A1 (ja) * | 2005-04-25 | 2006-11-02 | D. Western Therapeutics Institute, Inc. | ４－ブロモイソキノリン誘導体及びこれを含有する医薬 |
| JP4800720B2 (ja) * | 2005-09-21 | 2011-10-26 | 興和株式会社 | 点眼用組成物 |
| JP4168071B2 (ja) * | 2005-12-08 | 2008-10-22 | 興和株式会社 | 点眼用組成物 |
| ES2560603T3 (es) * | 2009-06-19 | 2016-02-22 | D. Western Therapeutics Institute, Inc. | Derivado de isoquinolina sustituida |
| CA2781390A1 (en) | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
| JP2012006918A (ja) * | 2010-05-27 | 2012-01-12 | Santen Pharmaceut Co Ltd | イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤 |
| EP2595665A1 (en) * | 2010-07-19 | 2013-05-29 | Inspire Pharmaceuticals, Inc. | Bifunctional rho kinase inhibitor compounds, composition and use |
| EP2597953A4 (en) * | 2010-07-27 | 2013-12-25 | Inspire Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF EYE DISEASES USING KINASE-INHIBITOR COMPOUNDS IN PRODRUG FORMS |
| JP2013129604A (ja) * | 2011-12-20 | 2013-07-04 | Kowa Co | 緑内障治療薬を含有する徐放性フィルム製剤 |
| EP3199155B1 (en) * | 2014-09-24 | 2021-06-16 | Kowa Company, Ltd. | Corneal thickness modulating agent |
-
2014
- 2014-03-03 CN CN201480013090.6A patent/CN105050600B/zh active Active
- 2014-03-03 TW TW103106973A patent/TWI629985B/zh not_active IP Right Cessation
- 2014-03-03 WO PCT/JP2014/001123 patent/WO2014174747A1/ja active Application Filing
- 2014-03-03 JP JP2014040041A patent/JP5557408B1/ja active Active
- 2014-03-03 US US14/362,850 patent/US20160339018A1/en not_active Abandoned
- 2014-03-03 EP EP14788679.0A patent/EP2990040B1/en active Active
- 2014-03-03 EP EP19199248.6A patent/EP3626245B1/en active Active
- 2014-03-03 KR KR1020157026982A patent/KR102177199B1/ko active IP Right Grant
- 2014-09-09 US US14/481,467 patent/US20140378441A1/en not_active Abandoned
-
2016
- 2016-03-07 HK HK16102561.7A patent/HK1214526A1/zh unknown
- 2016-12-21 US US15/387,113 patent/US10426783B2/en active Active
-
2019
- 2019-08-16 US US16/542,461 patent/US20190365776A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2990040A4 (en) | 2017-07-05 |
| US20190365776A1 (en) | 2019-12-05 |
| US20160339018A1 (en) | 2016-11-24 |
| US20140378441A1 (en) | 2014-12-25 |
| KR102177199B1 (ko) | 2020-11-10 |
| TW201440774A (zh) | 2014-11-01 |
| US20170100409A1 (en) | 2017-04-13 |
| EP2990040B1 (en) | 2019-12-04 |
| JP5557408B1 (ja) | 2014-07-23 |
| WO2014174747A1 (ja) | 2014-10-30 |
| CN105050600A (zh) | 2015-11-11 |
| EP2990040A1 (en) | 2016-03-02 |
| TWI629985B (zh) | 2018-07-21 |
| JP2014224090A (ja) | 2014-12-04 |
| EP3626245A1 (en) | 2020-03-25 |
| CN105050600B (zh) | 2018-09-28 |
| KR20150145229A (ko) | 2015-12-29 |
| US10426783B2 (en) | 2019-10-01 |
| EP3626245B1 (en) | 2021-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201321746D0 (en) | Therapeutic agents | |
| GB201321743D0 (en) | Therapeutic agents | |
| GB201321736D0 (en) | Therapeutic agents | |
| GB201321738D0 (en) | Therapeutic Agents | |
| GB201321729D0 (en) | Therapeutic agents | |
| GB201321733D0 (en) | Therapeutic agents | |
| GB201321728D0 (en) | Therapeutic agents | |
| GB201321739D0 (en) | Therapeutic agents | |
| GB201321730D0 (en) | Therapeutic agents | |
| HK1214526A1 (zh) | 眼底疾病治療劑 | |
| GB201321741D0 (en) | Therapeutic agents | |
| GB201321740D0 (en) | Therapeutic agents | |
| GB201321732D0 (en) | Therapeutic agents | |
| GB201321734D0 (en) | Therapeutic Agents | |
| GB201321737D0 (en) | Therapeutic Agents | |
| GB201321744D0 (en) | Therapeutic agents | |
| GB201321742D0 (en) | Therapeutic agents | |
| HK1219653A1 (zh) | 治療線粒體疾病的方法 | |
| GB201321735D0 (en) | Therapeutic Agents | |
| GB201321745D0 (en) | Therapeutic agents | |
| PL2959903T3 (pl) | Lek do leczenia chorób oczu | |
| EP2974730A4 (en) | MEDICINES FOR RESPIRATORY DISEASES | |
| GB201321731D0 (en) | Therapeutic agents | |
| GB201321748D0 (en) | Therapeutic agents | |
| HK1217910A1 (zh) | 骨用生物特異性試劑 |